BCL2L1 and cancer: High levels of NOXA expression can confer sensitivity to BCL-2/BCL-xL inhibitors (Lucas et al., 2012, Nakajima et al., 2014, Nalluri et al., 2015, Wang et al., 2014), and artificial expression of NOXA is sufficient to sensitize cancer cells to BCL-2/BCL-xL inhibitors (Nakajima et al., 2014), suggesting that increased NOXA expression is a contributing factor to ABT-263 sensitivity observed in MYCN-amplified neuroblastoma cells.